Table 1 Main clinical findings from (a) CLL (98 patients) and (b) MCL (64 patients)
From: TCL1A expression delineates biological and clinical variability in B-cell lymphoma
Clinical variables | Total |
---|---|
(a) CLL | |
Sex | |
Male | 60 |
Female | 38 |
Age at diagnosis (year)a | |
<60 | 34 |
60–69 | 30 |
⩾70 | 32 |
RAI stage | |
0 | 52 |
>0 | 46 |
Binet stage | |
A | 76 |
B+C | 22 |
CD38 expressiona | |
<20% | 65 |
⩾20% | 23 |
First-line treatment (at 60 months of follow-up) | |
Yes | 43 |
No | 55 |
(b) MCL | |
Sex | |
Male | 45 |
Female | 19 |
Agea | |
<60 years | 21 |
⩾60 years | 30 |
Stagesa | |
I | 0 |
II | 4 |
III | 7 |
IV | 48 |
Extranodal involvementa | |
<2 | 39 |
⩾2 | 25 |
Serum LDHa | |
⩽Normal | 38 |
>Normal | 12 |
ECOG performance statusa | |
<2 | 42 |
⩾2 | 11 |
International prognostic indexa | |
Low/low-intermediate | 27 |
High/high-intermediate | 25 |
Overall survival (at 60 months) | |
Alive | 36 |
Dead | 28 |